Theravance Biopharma will be acquired by Zymeworks for $17 per share, valuing TBPH at about $929 million, with shareholders receiving a CVR for 80% of future ampreloxetine net proceeds. The deal follows a comprehensive strategic review and monetization of the TRELEGY royalty, with closing anticipated in the second half of 2026, pending approvals. TBPH's strong YUPELRI franchise and ongoing ampreloxetine program anchor the value narrative.
Theravance Biopharma has agreed to a cash purchase by Zymeworks at $17 per share, valuing the company around $929 million and including a CVR for 80% of future ampreloxetine proceeds. The deal follows a comprehensive strategic review and targets closing in the second half of 2026, subject to approvals. The CVR adds optional upside if monetization opportunities materialize, potentially enhancing value beyond the cash offer.
Theravance Biopharma is initiating a strategic review, including a potential sale, following the failure of its experimental drug for blood pressure disorders in a late-stage trial. This development may significantly impact the company's financial health and investment strategies moving forward.
- Theravance Biopharma reported quarterly loss of $0.09 per share, beating estimates. - The company has surpassed consensus EPS estimates four times in the last four quarters. - Management's commentary on future earnings will impact stock movement. - Theravance Biopharma shares have underperformed the market by 16.6%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
